Nextida GC-B for improving post-meal blood sugar in adults with normal blood sugar or prediabetes

A Randomized, Triple-blind, Placebo Controlled, Parallel Clinical Trial to Investigate the Efficacy and Safety of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia or Prediabetes

This trial will test whether taking Nextida GC-B for 90 days improves post-meal blood sugar in adults with normal blood sugar or prediabetes compared with a placebo.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 60 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Rousselot BVBA (industry)
• Drugs / interventions: chemotherapy, radiation
• Locations: 1 site (London, Ontario)
• Trial ID: NCT07149064 on ClinicalTrials.gov

What this trial studies

Adults with normoglycemia or prediabetes and a BMI of 25–34.9 kg/m2 will receive either Nextida GC-B or a placebo and be followed for 90 days. The main measure is change from baseline in postprandial glucose using incremental area under the curve (iAUC 0–180 minutes) at Day 90. Safety and tolerability will also be monitored over the treatment period. Participants must meet reproductive-status requirements and attend visits at the study site.

Who should consider this trial

Good fit: Adults 18 years and older with BMI 25–34.9 kg/m2 who have normoglycemia or prediabetes and who meet the study's contraception or sterilization requirements are ideal candidates.

Not a fit: People with diagnosed diabetes, a BMI outside 25–34.9 kg/m2, pregnant women, or those unable to follow the contraceptive/sterilization requirements are unlikely to benefit from participation.

Why it matters

Potential benefit: If successful, Nextida GC-B could lower post-meal blood sugar and help reduce the risk of progression from prediabetes to diabetes.

How similar studies have performed: Other approaches to improving postprandial glycemic control have produced mixed results, and Nextida GC-B's effectiveness has not yet been established.

Eligibility criteria

Inclusion Criteria:

1. Males and females 18 years and older
2. BMI of 25 to 34.9 kg/m2, inclusive
3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening

   Or,

   Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
   1. Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
   2. Double-barrier method
   3. Intrauterine devices
   4. Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s)
   5. Vasectomy of partner at least 6 months prior to screening
   6. Abstinence and agrees to use contraception if planning on becoming sexually active during the study
4. Individuals with normoglycemia (HbA1c ≤5.9%) or prediabetes (HbA1c 6.0 to ≤6.4%) at screening
5. Stable body weight defined as a \<5% change in body weight in the three months prior to baseline as assessed by the Qualified Investigator (QI)
6. Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, sleep, and skin, nail and hair habits) as much as possible throughout the study
7. Willingness to complete questionnaires, records and diaries associated with the study, comply with continuous glucose monitor (CGM) device instructions, and complete all clinic visits
8. Provided voluntary, written, informed consent to participate in the study
9. Healthy as determined by medical history and laboratory results as assessed by QI

Exclusion Criteria:

1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
2. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational product, placebo or standardized meal ingredients
3. Metal implants or other physical characteristics/limitations that may affect DEXA scan results as assessed by the QI
4. Poor venous access as assessed by the QI
5. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Section 7.3)
6. Unstable metabolic disease or chronic diseases as assessed by the QI
7. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI
8. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
9. Type I or Type II diabetes
10. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
11. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months
12. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI
13. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI
14. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable
15. Individuals with an autoimmune disease or are immune compromised as assessed by the QI
16. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI
17. Self-reported confirmation of blood/bleeding disorders as assessed by the QI
18. Use of medical cannabinoid products
19. Chronic use of cannabinoid products (\>2 times/week). Occasional users will be required to washout and abstain for the duration of the study period
20. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period
21. Alcohol intake average of \>2 standard drinks per day as assessed by the QI
22. Alcohol or drug abuse within the last 12 months
23. Clinically significant abnormal laboratory results at screening as assessed by the QI
24. Blood donation 30 days prior to baseline, during the study, or a planned donation within 30 days of the last study visit
25. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI
26. Individuals who are unable to give informed consent
27. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant

Where this trial is running

London, Ontario

• KGK Science Inc. — London, Ontario, Canada (RECRUITING)

Study contacts

• Principal investigator: David Crowley, MD — KGK Science Inc.
• Study coordinator: Marc Moulin, PhD

Conditions: Normoglycemia, Prediabetes, Glycemic Control, Nextida GC-B, glycemic control, normoglycemia, postprandial glycemic control